contraindications for glp-1 Should Drugs Be Over the Counter? Clinical Focus on GLP-1 Agonists

The hypoglycemia risk deserves special attention, particularly for patients taking other diabetes medications

Large randomized clinical trials such as STEP 1 and SURMOUNT-1 have demonstrated mean total body weight reductions exceeding 10-20% with semaglutide and tirzepatide, respectively, positioning these medications as central components of contemporary obesity management [1,2]

Coverage for a GLP-1 test depends on the insurance policy and whether the test is deemed medically necessary

Plasma AUC of sitagliptin increased in a dose-proportional manner and increased approximately 14% following 100 mg doses at steady-state compared to the first dose

Liraglutide failed to induce FGF21 in both Wnt1 Glp1r/ (Supplemental Figs

Sterigenics continues to vigorously defend itself against claims of exposure and health risks linked to its Smyrna facility